Hunter Syndrome Therapeutics Market Global Report 2026

The hunter syndrome therapeutics market size has grown strongly in recent years. It will grow from $1.24 billion in 2025 to $1.33 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increasing availability of enzyme replacement therapy products, growing awareness of lysosomal storage disorders among healthcare professionals, expansion of orphan drug regulatory incentives, rising investments in rare disease clinical research, improving access to specialized treatment centers.

The hunter syndrome therapeutics market size is expected to see strongly grown in the next few years. It will grow to $1.78 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to advancement of gene therapy platforms for hunter syndrome treatment, increasing adoption of precision medicine approaches, expansion of newborn screening initiatives for early detection, growing pipeline of next generation therapeutic candidates, rising collaborations between biotechnology companies and research institutions. Major trends in the forecast period include increasing adoption of enzyme replacement therapies for long term disease management, growing clinical development of gene therapies targeting iduronate-2-sulfatase deficiency, rising focus on early diagnosis and newborn screening programs for hunter syndrome, expanding use of personalized treatment approaches based on disease severity, increasing investments in rare disease research and orphan drug development.

The increasing healthcare investment in rare diseases is expected to propel the growth of the hunter syndrome therapeutics market going forward. Rare diseases refer to disorders that affect fewer than 1 in 2,000 people, often involving complex symptoms and limited treatment options. Healthcare investment in rare diseases is rising due to increasing government incentives such as orphan drug policies, tax credits, and regulatory support, which encourage pharmaceutical companies to invest in the development of treatments for small and underserved patient populations. Healthcare investment in rare diseases drives the development of hunter syndrome therapeutics by providing funding, regulatory incentives, and research support that enable the advancement, clinical testing, and commercialization of enzyme replacement therapies and gene therapies for this rare genetic disorder with limited treatment options. For instance, in April 2024, according to Global Genes, a US-based nonprofit organization, in the first quarter of 2024, companies developing drugs for rare diseases raised $7.1 billion through public equity and debt financings, a 307% surge compared to the $1.8 billion raised in the same period of 2023. Therefore, the increasing healthcare investment in rare diseases is driving the growth of the hunter syndrome therapeutics market.

Major companies operating in the hunter syndrome therapeutics market are focusing on developing innovative therapies, such as blood-brain barrier-crossing biologic therapy, to improve neurological drug delivery, reduce disease progression, and enhance treatment outcomes in patients with Hunter syndrome. Blood-brain barrier-crossing biologic therapy is an advanced treatment approach that delivers therapeutic agents across the blood-brain barrier into the brain, helping improve neurological symptoms, slow disease progression, and enhance overall clinical outcomes in central nervous system disorders. For instance, in March 2026, Denali Therapeutics Inc., a US-based biopharmaceutical company, received U.S. Food and Drug Administration approval for Avlayah (tividenofusp alfa-eknm), a novel therapy for treating certain neurologic manifestations of Hunter syndrome (MPS II). The treatment is designed to cross the blood-brain barrier using advanced transport technology, enabling targeted enzyme delivery to affected tissues in the central nervous system and peripheral organs. It is intended to reduce glycosaminoglycan accumulation, improve neurological function, and address both cognitive and systemic symptoms associated with the disease, marking a significant advancement in rare disease therapeutic innovation.

In May 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired AVROBIO Inc.’s investigational cystinosis gene therapy program for $87.5 million. With this acquisition, Novartis AG aims to strengthen its rare disease and gene therapy pipeline by adding a late-stage hematopoietic stem cell-based treatment for cystinosis, thereby expanding its capabilities in innovative genetic medicine targeting rare metabolic disorders. AVROBIO Inc. is a US-based clinical-stage biotechnology company that specializes in developing gene and cell therapies, including one-time lentiviral gene therapy (AVR-RD-05) for Hunter syndrome (MPS II).

Major companies operating in the hunter syndrome therapeutics market are Takeda Pharmaceutical Company Limited; Denali Therapeutics Inc.; Sanofi S.A.; GC Biopharma Corporation; Ultragenyx Pharmaceutical Inc.; JCR Pharmaceuticals Co. Ltd.; REGENXBIO Inc.

North America was the largest region in the hunter syndrome therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hunter syndrome therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hunter syndrome therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hunter syndrome therapeutics market consists of sales of prescription medicines, biologic formulations, and supportive treatment drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and healthcare providers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The hunter syndrome therapeutics market research report is one of a series of new reports that provides hunter syndrome therapeutics market statistics, including hunter syndrome therapeutics industry global market size, regional shares, competitors with a hunter syndrome therapeutics market share, detailed hunter syndrome therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the hunter syndrome therapeutics industry. This hunter syndrome therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.